Brilinta approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease

1 June 2020 - New Brilinta indication expands treatment to high-risk coronary patients without a history of stroke or heart ...

Read more →

Lilly's Taltz (ixekizumab) is the first IL-17A antagonist to receive U.S. FDA approval for the treatment of non-radiographic axial spondyloarthritis

1 June 2020 - Taltz is now approved to treat patients across the full axSpA spectrum, including ankylosing spondylitis, also known ...

Read more →

Health economic assessment of Vimizim in mucopolysaccharidosis type IVA (Morquio A syndrome)

29 May 2020 - TLV has developed a health economic knowledge base for the regions of the drug Vimizim (elosulfase alfa) ...

Read more →

Zionexa USA and PETNET Solutions announce FDA approval of Cerianna (Fluoroestradiol F 18)

27 May 2020 - Zionexa USA and PETNET Solutions have announced that the FDA has approved Cerianna (fluoroestradiol F 18) injection ...

Read more →

U.S. FDA approves new paediatric formulation of Sirturo (bedaquiline) as part of combination therapy to treat children with pulmonary multidrug-resistant tuberculosis

27 May 2020 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. FDA has granted ...

Read more →

CHMP issues positive opinion to extend Invokana (canagliflozin) indication to reflect improved renal outcomes in patients with diabetic kidney disease and type 2 diabetes

29 May 2020 - Positive opinion is based on the Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation ...

Read more →

Menlo Therapeutics receives FDA approval of Zilxi (minocycline) 1.5 % topical foam, the first topical minocycline treatment for rosacea

29 May 2020 - Zilxi now approved for inflammatory lesions of rosacea in adults. ...

Read more →

Boehringer Ingelheim receives positive CHMP opinion for a third nintedanib indication in pulmonary fibrosis

29 May 2020 - The opinion is for the treatment of adults with other chronic fibrosing interstitial lung diseases with a ...

Read more →

Takeda receives positive CHMP opinion for pre-filled syringe presentation of Takhzyro (lanadelumab) for use as a preventive treatment for hereditary angioedema attacks

29 May 2020 - Validation of type II variation will allow Takeda to commence launches in Europe later this year. ...

Read more →

Nabriva Therapeutics receives positive EU CHMP opinion for Xenleta (lefamulin) for the treatment of community-acquired pneumonia

29 May 2020 - If approved, Xenleta has the potential to be a first-in-class pleuromutilin antibiotic for the intravenous and ...

Read more →

Johnson & Johnson receives positive CHMP opinion for Janssen’s investigational preventive Ebola vaccine regimen

29 May 2020 - The investigational Ebola vaccine regimen leverages Janssen’s established AdVac and PER.C6 technologies and Bavarian Nordic’s MVA-BN technology. ...

Read more →

CHMP recommends EU approval of Roche’s Rozlytrek for people with NTRK fusion-positive solid tumours and for people with ROS1-positive, advanced non-small cell lung cancer

29 May 2020 - Rozlytrek has shown durable responses across multiple tumour types, including cancer that has spread to the brain, ...

Read more →

Novartis Piqray receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation

29 May 2020 - Piqray (alpelisib) in combination with fulvestrant will become first and only targeted treatment for advanced breast ...

Read more →

FDA approves Genentech’s Tecentriq in combination with Avastin for people with the most common form of liver cancer

29 May 2020 - Application approved under FDA’s Project Orbis initiative and Real-Time Oncology Review pilot program. ...

Read more →

Highlights from the May 25-28 CHMP meeting

29 May 2020 - Eight new medicines recommended for approval. ...

Read more →